178 related articles for article (PubMed ID: 32813314)
21. Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study.
Bello N; Birt JA; Workman J; Zhou X; Ross-Terres JA; Petri M
Adv Ther; 2022 Jul; 39(7):3131-3145. PubMed ID: 35534786
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
[TBL] [Abstract][Full Text] [Related]
23. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
Ruiz-Irastorza G; Ugarte A; Egurbide MV; Garmendia M; Pijoan JI; Martinez-Berriotxoa A; Aguirre C
Ann Rheum Dis; 2007 Jun; 66(6):815-7. PubMed ID: 17204564
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer in systemic lupus.
Bernatsky S; Ramsey-Goldman R; Petri M; Urowitz MB; Gladman DD; Fortin PR; Ginzler E; Romero-Diaz J; Peschken C; Jacobsen S; Hanly JG; Gordon C; Nived O; Yelin EH; Isenberg D; Rahman A; Bae SC; Joseph L; Witte T; Ruiz-Irastorza G; Aranow C; Kamen D; Sturfeldt G; Foulkes WD; Hansen JE; St Pierre Y; Raymer PC; Tessier-Cloutier B; Clarke AE
Lupus; 2017 Mar; 26(3):311-315. PubMed ID: 27687028
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
26. Serum uric acid is associated with damage in patients with systemic lupus erythematosus.
Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cardenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
Lupus Sci Med; 2020; 7(1):e000366. PubMed ID: 32153795
[TBL] [Abstract][Full Text] [Related]
27. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
[TBL] [Abstract][Full Text] [Related]
28. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.
Hsu CY; Lin MS; Su YJ; Cheng TT; Lin YS; Chen YC; Chiu WC; Chen TH
Rheumatology (Oxford); 2017 Apr; 56(4):620-628. PubMed ID: 28039419
[TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
Guo JY; Ren ZG; Xuan YY; Li TF; Liu XJ; Niu CZ; Li JY; Liu SY
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):218-221. PubMed ID: 32146749
[TBL] [Abstract][Full Text] [Related]
30. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.
Pokroy-Shapira E; Gelernter I; Molad Y
Clin Rheumatol; 2014 May; 33(5):649-57. PubMed ID: 24535410
[TBL] [Abstract][Full Text] [Related]
31. [The occurrence of malignancies in a Hungarian lupus population].
Tarr T; Szekanecz E; Zeher M; Szegedi G; Kiss E
Orv Hetil; 2006 Nov; 147(46):2229-33. PubMed ID: 17396395
[TBL] [Abstract][Full Text] [Related]
32. Invasive fungal infections in Argentine patients with systemic lupus erythematosus.
Vinicki JP; Catalan Pellet S; Pappalardo C; Cruzat VC; Spinetto MA; Dubinsky D; Tiraboschi IN; Laborde HA; Nasswetter G
Lupus; 2013 Aug; 22(9):892-8. PubMed ID: 23861029
[TBL] [Abstract][Full Text] [Related]
33. Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study.
Dey D; Kenu E; Isenberg DA
Lupus; 2013 Aug; 22(9):919-27. PubMed ID: 23857987
[TBL] [Abstract][Full Text] [Related]
34. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs.
Feldman CH; Liu J; Feldman S; Solomon DH; Kim SC
Lupus; 2017 Jun; 26(7):682-689. PubMed ID: 27799438
[TBL] [Abstract][Full Text] [Related]
35. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.
Hanly JG; Urowitz MB; Su L; Gordon C; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Wallace DJ; Clarke AE; Ginzler E; Merrill JT; Isenberg DA; Rahman A; Petri M; Fortin PR; Gladman D; Bruce IN; Steinsson K; Dooley M; Khamashta MA; Alarcón GS; Fessler BJ; Ramsey-Goldman R; Manzi S; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven R; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Theriault C; Thompson K; Farewell V
Ann Rheum Dis; 2012 Sep; 71(9):1502-9. PubMed ID: 22492779
[TBL] [Abstract][Full Text] [Related]
36. [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Wang L; Yang Y; Jia Y; Miao H; Zhou YS; Zhang XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1081-1085. PubMed ID: 27987518
[TBL] [Abstract][Full Text] [Related]
37. Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes.
Rúa-Figueroa I; López-Longo FJ; Del Campo V; Galindo-Izquierdo M; Uriarte E; Torre-Cisneros J; Vela P; Tomero E; Narváez J; Olivé A; Freire M; Salgado E; Andreu JL; Martínez-Taboada V; Calvo-Alén J; Hernández-Cruz B; Raya E; Quevedo V; Expósito Pérez L; Fernández-Nebro A; Ibañez M; Pascual-Valls È; Rúa-Figueroa D; Naranjo A; Pego-Reigosa JM
J Rheumatol; 2020 Feb; 47(2):234-240. PubMed ID: 30988123
[TBL] [Abstract][Full Text] [Related]
38. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.
Pimentel-Quiroz VR; Ugarte-Gil MF; Harvey GB; Wojdyla D; Pons-Estel GJ; Quintana R; Esposto A; García MA; Catoggio LJ; Cardiel MH; Barile LA; Amigo MC; Sato EI; Bonfa E; Borba E; Lavras Costallat LT; Neira OJ; Massardo L; Guibert-Toledano M; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2019 Aug; 28(9):1101-1110. PubMed ID: 31291843
[TBL] [Abstract][Full Text] [Related]
39. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
40. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
